Breaking News Instant updates and real-time market news.

AKBA

Akebia

$4.05

0.35 (9.46%)

10:58
11/10/19
11/10
10:58
11/10/19
10:58

Akebia announces 'positive' data from two Phase 3 vadadustat studies

Akebia Therapeutics announced that MTPC, Akebia's development and commercialization collaboration partner in Japan for vadadustat, presented positive 24-week and 52-week data from two Phase 3 active-controlled pivotal studies evaluating the efficacy and safety of vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese patients with anemia due to chronic kidney disease, at ASN Kidney Week 2019. Each study met its primary endpoint based on mean hemoglobin level at weeks 20 and 24, and showed vadadustat's effect on hemoglobin was sustained through to 52 weeks in each study.

  • 12

    Nov

AKBA Akebia
$4.05

0.35 (9.46%)

06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper says buy Akebia before market figures out competitive positoin
After hosting an investor call with Akebia Therapeutics (AKBA) CEO John Butler, Piper Jaffray analyst Christopher Raymond thinks vadadustat's competitive position relative to FibroGen's (FGEN) roxadustat is "stronger, not weaker now." As such, the analyst recommends buying shares of Akebia "before the market begins to figure this out." Raymond left the call incrementally confident in vadadustat "on a number of levels," namely its approvability given Akebia's alignment with FDA on trial design and statistical analysis. He keeps an Overweight rating on the shares with a $22 price target.
07/24/19
HCWC
07/24/19
NO CHANGE
Target $19
HCWC
Buy
Akebia shares at 'excellent entry point,' says H.C. Wainwright
After Akebia (AKBA) announced that its Japanese partner on vadadustat has submitted a New Drug Application in Japan that supports approval for anemia due to chronic kidney disease in both non-dialysis and dialysis patients, H.C. Wainwright analyst Ed Arce noted that this represents the first regulatory submission for vadadustat. The current valuation, with shares trading near 52-week lows, presents "an excellent entry point" given that the primary bear thesis depends on the first-to-market advantage of Fibrogen's (FGEN) roxadustat, which Arce views as "fundamentally flawed," he tells investors. In light of the JNDA submission, as well as the current timeline, Arce pushed back his U.S. and EU market launch and initial sales estimates to early 2022 and trimmed his price target on Akebia shares to $19 from $21, but he keeps a Buy rating on the stock.
08/08/19
PIPR
08/08/19
NO CHANGE
Target $22
PIPR
Overweight
Akebia's Auryxia 'a nice little growth story,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and $22 price target on Akebia's shares following the company's Q2 update. While the analyst is "gratified" to see the shares up 11% on a robust Auryxia print, the analyst believes this company still has an EV $300M, despite possessing a $130M/year approved drug, and a potential $1B product - vadadustat - with Phase 3 readouts next year. Raymond thinks the totality of the data would indicate that, despite being the second HIF to the market, vadadustat is differentiated enough, and the market is large enough that vadadustat has blockbuster potential. In the meantime, he would argue this stock's current valuation is more than justified by Auryxia alone
10/16/19
HCWC
10/16/19
NO CHANGE
Target $17
HCWC
Buy
Akebia lawsuit against CMS right course of action, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce views Akebia Akebia Therapeutics' lawsuit against the Centers for Medicare & Medicaid Services and the U.S. Department of Health and Human Services as a "positive step." After a year of "extensive outreach and unsuccessful interactions" with CMS, Akebia now seeks to reverse both adverse decisions on Auryxia, and restore appropriate coverage and access to the drug, Arce tells investors in a research note partially titled "Enough Is Enough." The analyst believes "this bold step is the right course of action" for Akebia and he expects anticipate "some positive resolution" will serve as a catalyst for the shares. He reiterates a Buy rating on Akebia with a $17 price target.

TODAY'S FREE FLY STORIES

SKY

Skyline

$30.99

-0.45 (-1.43%)

12:48
11/22/19
11/22
12:48
11/22/19
12:48
Recommendations
Skyline analyst commentary  »

SunTrust boosts Skyline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:47
11/22/19
11/22
12:47
11/22/19
12:47
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

12:46
11/22/19
11/22
12:46
11/22/19
12:46
Periodicals
Breaking Periodicals news story on We Company, SoftBank, SoftBank »

WeWork chairman lays out…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Z

Zillow

$41.03

1.22 (3.06%)

12:45
11/22/19
11/22
12:45
11/22/19
12:45
Options
Zillow call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
11/22/19
11/22
12:45
11/22/19
12:45
General news
Breaking General news story  »

Week of 11/22…

12:45
11/22/19
11/22
12:45
11/22/19
12:45
General news
Breaking General news story  »

Week of 11/22…

12:42
11/22/19
11/22
12:42
11/22/19
12:42
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

BIIB

Biogen

$294.17

5.51 (1.91%)

12:33
11/22/19
11/22
12:33
11/22/19
12:33
Periodicals
Breaking Periodicals news story on Biogen »

Biogen settles Tecfidera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

BIIB

Biogen

$293.68

5.02 (1.74%)

12:26
11/22/19
11/22
12:26
11/22/19
12:26
Hot Stocks
Breaking Hot Stocks news story on Biogen »

Biogen rallies 3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

FTCH

Farfetch

$9.73

0.335 (3.57%)

12:25
11/22/19
11/22
12:25
11/22/19
12:25
Options
Farfetch Limited call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$310.63

0.34 (0.11%)

12:18
11/22/19
11/22
12:18
11/22/19
12:18
General news
Ray Dalio says WSJ wrong, Bridgewater not betting market will fall »

Ray Dalio, Co-Chief…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$310.63

0.34 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/22/19
11/22
12:17
11/22/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/22/19
11/22
12:16
11/22/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.30

-0.425 (-0.79%)

12:15
11/22/19
11/22
12:15
11/22/19
12:15
Options
Dell Technologies put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 02

    Dec

  • 09

    Dec

  • 09

    Dec

12:15
11/22/19
11/22
12:15
11/22/19
12:15
General news
Treasury Action: the markets are mixed with no strong directional drivers »

Treasury Action: the…

RF

Regions Financial

$16.68

0.19 (1.15%)

12:05
11/22/19
11/22
12:05
11/22/19
12:05
Options
Regions Financial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

SPCE

Virgin Galactic

$7.57

-0.88 (-10.41%)

12:00
11/22/19
11/22
12:00
11/22/19
12:00
Hot Stocks
Virgin Galactic falls -10.3% »

Virgin Galactic is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PSTG

Pure Storage

$16.24

-3.6 (-18.15%)

12:00
11/22/19
11/22
12:00
11/22/19
12:00
Hot Stocks
Pure Storage falls -18.2% »

Pure Storage is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

  • 12

    Dec

  • 10

    Mar

  • 11

    Mar

DAC

Danaos

$5.65

-1.68 (-22.92%)

12:00
11/22/19
11/22
12:00
11/22/19
12:00
Hot Stocks
Danaos falls -26.2% »

Danaos is down -26.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

GSX

GSX Techedu

$18.88

2.625 (16.15%)

12:00
11/22/19
11/22
12:00
11/22/19
12:00
Hot Stocks
GSX Techedu rises 16.5% »

GSX Techedu is up 16.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BKE

The Buckle

$26.24

3.9 (17.46%)

12:00
11/22/19
11/22
12:00
11/22/19
12:00
Hot Stocks
The Buckle rises 17.4% »

The Buckle is up 17.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

SSI

Stage Stores

$4.30

0.95 (28.36%)

12:00
11/22/19
11/22
12:00
11/22/19
12:00
Hot Stocks
Stage Stores rises 27.7% »

Stage Stores is up 27.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$219.83

1.6 (0.73%)

, JPM

JPMorgan

$130.91

0.95 (0.73%)

11:57
11/22/19
11/22
11:57
11/22/19
11:57
On The Fly
Fly Intel: Wall Street's top stories at midday »

Markets were mixed near…

GS

Goldman Sachs

$219.83

1.6 (0.73%)

JPM

JPMorgan

$130.91

0.95 (0.73%)

TSLA

Tesla

$332.94

-21.88 (-6.17%)

F

Ford

$8.84

0.115 (1.32%)

GM

General Motors

$35.30

0.64 (1.85%)

GPS

Gap

$16.69

0.47 (2.90%)

UBER

Uber

$29.59

0.13 (0.44%)

HIBB

Hibbett Sports

$29.00

3.93 (15.68%)

JWN

Nordstrom

$37.50

3.21 (9.36%)

SPLK

Splunk

$135.96

9.16 (7.22%)

PSTG

Pure Storage

$16.26

-3.58 (-18.04%)

FL

Foot Locker

$39.54

-1.92 (-4.63%)

WSM

Williams-Sonoma

$66.86

-1.9 (-2.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 22

    Nov

  • 02

    Dec

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 14

    Jan

  • 15

    Jan

  • 04

    Feb

  • 10

    Mar

  • 11

    Mar

ACM

Aecom

$42.48

0.095 (0.22%)

11:55
11/22/19
11/22
11:55
11/22/19
11:55
Conference/Events
Aecom participates in a conference call with BofA/Merrill »

Aecom discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 10

    Dec

DE

Deere

$176.24

0.18 (0.10%)

11:46
11/22/19
11/22
11:46
11/22/19
11:46
Conference/Events
Deutsche Bank machinery analysts to hold an analyst/industry conference call »

Machinery Analysts, along…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 03

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.